Elisa Zanini, Nicole Forster-Gross, Felix Bachmann, Adrian Brüngger, Paul McSheehy, Karine Litherland, Karin Burger, Anna C. Groner, Mila Roceri, Luc Bury, Martin Stieger, Nicole Willemsen-Seegers, Jos de Man, Diep Vu-Pham, Helma W. E. van Riel, Guido J. R. Zaman, Rogier
The Crossfire team will present 3 posters at the American Association for Cancer Research (AACR) annual meeting 2024. We will highlight the latest data on our best-in-class macrocyclic BTK inhibitor CFON-026, our novel Degrader Antibody Conjugate (DAC) technology, and our
Today Crossfire Oncology B.V. (Crossfire) has entered its brand-new state-of-the-art chemistry and molecular biology laboratories at the Marie Curie Building (Pivot Park, Oss). The new facilities will enable Crossfire to expand their activities in developing kinase Degrader Antibody Conjugates (DACs)